Engitix is a biotechnology company focused on extracellular matrix (ECM) science to improve drug discovery and development for chronic diseases. It uses proprietary human ECM-based platforms, 3D cell models, bioarchives, bioinformatics, AI and machine learning to identify novel drug targets, biomarkers and therapeutic candidates. The company’s work centres on fibrosis, inflammation and solid tumours, with internal discovery-stage programmes and collaborations with pharmaceutical partners. Its services and capabilities support more predictive preclinical research, disease modelling and translational insights, helping partners understand complex disease biology and advance potential first- and best-in-class medicines.
